Highlights
- Market Cap
- $791.49M
- Enterprise Value
- $750.17M
- EPS (TTM)
- -$1.74
- Total Revenue (TTM)
- $84.28M
- Gross Profit (TTM)
- $45.85M
- EBITDA (TTM)
- -$175.98M
- Year Range
- $6.66 - $18.90
- Target Price
- $31.00
- ROA (TTM)
- -52.28%
- ROE (TTM)
- -149.92%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Silverback Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Silverback Therapeutics Inc (SPRY) has returned -31.07% so far this year and -36.17% over the past 12 months.
Silverback Therapeutics Inc
- 1D
- 2.75%
- 1M
- -13.47%
- YTD
- -31.07%
- 6M
- -20.10%
- 1Y
- -36.17%
- 3Y*
- 7.25%
- 5Y*
- -28.93%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Dec 4, 2020, SPRY's average daily return is +0.05%, while the average monthly return is +0.70%. At this rate, your investment would double in approximately 8.3 years.
Historically, 47% of months were positive and 53% were negative. The best month was Dec 2020 with a return of +85.4%, while the worst month was Sep 2021 at -54.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.
On a daily basis, SPRY closed higher 49% of trading days. The best single day was May 12, 2023 with a return of +77.9%, while the worst single day was Sep 20, 2023 at -55.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.25% | -7.11% | -13.47% | -31.07% | |||||||||
| 2025 | 23.41% | -19.51% | 20.04% | 11.05% | 3.29% | 20.93% | 1.32% | -34.28% | -13.51% | -10.85% | 6.47% | 22.12% | 10.43% |
| 2024 | 13.32% | 34.78% | 22.10% | -14.87% | 2.07% | -4.17% | 27.73% | 19.41% | 11.71% | 1.52% | -1.43% | -27.29% | 92.52% |
| 2023 | -19.58% | 30.03% | -27.02% | -0.15% | 7.08% | -3.74% | 9.70% | -3.54% | -46.69% | -5.56% | 35.29% | 13.46% | -35.76% |
| 2022 | -26.88% | -11.70% | -18.37% | -11.40% | 12.22% | 21.49% | 21.70% | 5.43% | -2.94% | 17.80% | 0.00% | 37.14% | 28.08% |
| 2021 | -5.22% | 9.43% | -9.22% | -26.54% | -14.10% | 12.20% | -1.97% | -27.34% | -54.64% | -13.53% | -18.54% | -5.26% | -85.63% |
Benchmark Metrics
Silverback Therapeutics Inc has an annualized alpha of -1.12%, beta of 1.06, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 07, 2020.
- This stock participated in 174.31% of S&P 500 Index downside but only 51.05% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -1.12%
- Beta
- 1.06
- R²
- 0.05
- Upside Capture
- 51.05%
- Downside Capture
- 174.31%
Return for Risk
Risk / Return Rank
SPRY ranks 20 for risk / return — below 20% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Silverback Therapeutics Inc (SPRY) and compare them to a chosen benchmark (S&P 500 Index).
| SPRY | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.54 | 0.90 | -1.44 |
Sortino ratioReturn per unit of downside risk | -0.50 | 1.39 | -1.88 |
Omega ratioGain probability vs. loss probability | 0.94 | 1.21 | -0.27 |
Calmar ratioReturn relative to maximum drawdown | -0.56 | 1.40 | -1.96 |
Martin ratioReturn relative to average drawdown | -0.97 | 6.61 | -7.58 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore SPRY risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Silverback Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Silverback Therapeutics Inc was 95.20%, occurring on May 11, 2022. The portfolio has not yet recovered.
The current Silverback Therapeutics Inc drawdown is 86.71%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.2% | Mar 18, 2021 | 291 | May 11, 2022 | — | — | — |
| -18.82% | Jan 4, 2021 | 3 | Jan 6, 2021 | 4 | Jan 12, 2021 | 7 |
| -16.61% | Mar 3, 2021 | 3 | Mar 5, 2021 | 5 | Mar 12, 2021 | 8 |
| -14.85% | Jan 15, 2021 | 15 | Feb 5, 2021 | 7 | Feb 17, 2021 | 22 |
| -8.62% | Feb 18, 2021 | 4 | Feb 23, 2021 | 4 | Mar 1, 2021 | 8 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Silverback Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Silverback Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SPRY relative to other companies in the Biotechnology industry. Currently, SPRY has a P/S ratio of 9.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SPRY in comparison with other companies in the Biotechnology industry. Currently, SPRY has a P/B value of 6.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |